Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Safety and Immunogenicity of H7N9 LAIV in Healthy Adults
NCT03739229Phase 1Unknown
- Sponsor
- Smorodintsev Research Institute of Influenza
- Start
- Dec 2018
- Primary completion
- Jun 2019
- Modality
- Vaccines & Immunotherapeutics
01
Overview
Phase 1, randomised, double-blind trial in influenza comparing H7N9 LAIV with Placebo (2 arms). Primary endpoints: Number of Participants with Immediate reactions at 2 hours, Number of Participants with Solicited adverse events at 6 days and 2 more. Status: unknown.
02
Drugs
H7N9 Anhui 2013/AA ca
03
Conditions
influenza
Beyond the preview
Go deeper on NCT03739229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT03739229.